share_log

Huaxia Eye Hospital GroupLtd's (SZSE:301267) Soft Earnings Don't Show The Whole Picture

Huaxia Eye Hospital GroupLtd's (SZSE:301267) Soft Earnings Don't Show The Whole Picture

華夏眼科醫院集團有限公司(SZSE:301267)的業績不佳並不能完全展現整體情況
Simply Wall St ·  11/05 08:01

The most recent earnings report from Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement.

華夏眼科醫院集團有限公司(SZSE:301267)最新的收益報告令股東們失望。儘管利潤數字不佳,但我們的分析對於財務報表的整體質量持樂觀態度。

big
SZSE:301267 Earnings and Revenue History November 5th 2024
SZSE:301267盈利和營業收入歷史2024年11月5日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Huaxia Eye Hospital GroupLtd's profit was reduced by CN¥123m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If Huaxia Eye Hospital GroupLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

重要的是,我們的數據顯示,華夏眼科醫院集團有限公司的利潤今年因飛凡項目減少了人民幣12300萬。看到飛凡項目影響公司利潤並不是好事,但好消息是,情況可能會變得更好。我們研究了成千上萬家上市公司,發現飛凡項目往往是一次性的。鑑於這些項目被認爲是不尋常的,這並不奇怪。如果華夏眼科醫院集團有限公司不再出現這些不尋常的費用,其他條件相同的情況下,我們預計其利潤將在未來一年內增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Huaxia Eye Hospital GroupLtd's Profit Performance

我們對華夏眼科醫院集團有限公司的利潤表現的看法

Because unusual items detracted from Huaxia Eye Hospital GroupLtd's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Huaxia Eye Hospital GroupLtd's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at 5.9% per year over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Huaxia Eye Hospital GroupLtd, you'd also look into what risks it is currently facing. Case in point: We've spotted 1 warning sign for Huaxia Eye Hospital GroupLtd you should be aware of.

由於飛凡項目在華夏眼科醫院集團Ltd的收入中扣除了過去一年的收益,因此我們可以預期當前季度有所改善。根據這一觀察,我們認爲華夏眼科醫院集團Ltd的財務利潤實際上低估了其盈利潛力!而且,其每股收益在過去三年中以5.9%的速度增長。本文的目標是評估我們能否依靠財務利潤來反映該公司的潛力,但還有很多要考慮的其他因素。如果您想深入了解華夏眼科醫院集團Ltd,您還應該了解它目前面臨的風險。舉例來說:我們發現了一項警示信號,提醒您需要留意的。

This note has only looked at a single factor that sheds light on the nature of Huaxia Eye Hospital GroupLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這則說明只看了一個能夠揭示華夏眼科醫院集團Ltd利潤性質的因素。但有許多其他方式可以幫助您了解公司。一些人認爲,高股本回報率是優質企業的好跡象。儘管這可能需要您進行一些研究,您可能會發現這份免費的高股本回報率公司收集,或者這份持有大量內部持股的股票清單對您有所幫助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論